Sunstone Life Science Ventures focuses on investing in early-stage European life science companies that are developing novel therapeutics for humans. Their strategy emphasizes opportunities with strong global potential, targeting unmet medical needs in commercially attractive niche markets, specialty pharma, and orphan drug indications, often investing when drug candidates are in pre-clinical or clinical phase I.
80% of their portfolio is in Biotech & Life Sciences. They made 1 investments in the last 12 months. Their most common stage is series-b (40% of deals). Average disclosed round size is $60.8M (across 5 rounds with reported amounts).
Portfolio
5
Fund Size
$500M
Top Stage
Series B
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Step Pharma | Series C | $38M | Oct 2025 |
| TTeitur Trophics | Series A | $28M | Mar 2023 |
| MMinervaX | Series B | $72M | Dec 2022 |
 TargED Biopharmaceuticals | Series A | $39M | Feb 2022 |
 IO Biotech | Series B | $127M | Jan 2021 |
Top Co-Investors
Kurma Partners2 shared
Industrifonden2 shared
Hadean Ventures2 shared
Vivo Capital1 shared
RA Capital Management1 shared
Samsara BioCapital1 shared
Idinvest1 shared
PFM Health Sciences1 shared
Soleus Capital1 shared
EI Ventures1 shared
Trill Impact1 shared
Pureos Bioventures1 shared
Wellington Management1 shared
Sanofi Ventures1 shared
Andera Partners1 shared
Fund+1 shared
INKEF Capital1 shared
Pontifax1 shared
Bpifrance1 shared
Last updated: 7 April 2026